RT Journal Article
SR Electronic
T1 Gabapentin as add-on to fentanyl and midazolam in patients receiving mechanical ventilation: a randomized, blinded study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 340
DO 10.1183/13993003.congress-2020.340
VO 56
IS suppl 64
A1 Bagheri, Bahador
A1 Salarian, Sara
A1 Taherkhanchi, Bahar
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/340.abstract
AB Background: Fentanyl and midazolam are used in management of patients requiring mechanical ventilation. They are usually associated with important unwanted effects. Gabapentin has sedative and analgesic effects. Our purpose was to study gabapentin addition on total consumption of fentanyl and midazolam in patients receiving mechanical ventilation.Methods: This randomized and double-blinded trial was conducted in ICU of a general hospital, Tehran, Iran. Fifty patients aged from 18 to 70 years were randomized 1:1 to 300 mg gabapentin q8hr plus 0.5 - 2 µg/kg/hour fentanyl and 0.05 - 0.1 mg/kg/hour midazolam or identical placebo plus 0.5 - 2 µg/kg/hour fentanyl and 0.05 - 0.1 mg/kg/hour midazolam. Daily use of fentanyl and midazolam were measured. Ramsay sedation score was used for evaluation of sedation.Results: A total of 43 patients were studied. Both treatment modalities reached the target sedation level. Mean total dose of midazolam was 3.9 ± 2.1 mg in the control group and 2.3 ± 2.1 mg in the intervention group (P < 0.05). For fentanyl, it was 29.4 ± 16.2 µg in the control group and 13.3 ± 11.1 µg in the intervention group (P < 0.01). No significant differences were observed in duration of ventilation and length of ICU stay. No case of severe adverse effect was observedConclusion: This trial showed that add-on therapy with gabapentin can significantly reduce total consumption of fentanyl and midazolam in patients receiving mechanical ventilation. Gabapentin addition to fentanyl and midazolam has no significant impact on duration of ventilation and length of ICU stay.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 340.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).